Kairos Pharma, LTD.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $2.1M | $414,000 | $82,000 | — |
| Operating expenses | $5.6M | $2.3M | $1.7M | — |
| Operating income | -$5.6M | -$2.3M | -$1.7M | — |
| Interest expense | — | $35,000 | $42,000 | — |
| Net income | -$5.4M | -$2.6M | -$1.8M | — |
| Balance Sheet | ||||
| Cash and equivalents | $4.5M | $1.3M | — | — |
| Current assets | $5.4M | $4.2M | $101,000 | — |
| Total assets | $6.5M | $5.8M | $965,000 | — |
| Current liabilities | $199,000 | $992,000 | $2.4M | — |
| Total liabilities | — | $992,000 | $3.0M | — |
| Stockholders' equity | $6.3M | $4.8M | -$2.1M | -$1.2M |
| Cash Flow Statement | ||||
| Cash from operations | -$3.4M | -$4.0M | $81,000 | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 21.4M · Free float 68.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.